{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:19:28Z","timestamp":1781885968995,"version":"3.54.5"},"reference-count":48,"publisher":"American Diabetes Association","issue":"10","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,10,1]]},"abstract":"<jats:p>OBJECTIVE\u2014Adiponectin and resistin, two recently discovered adipocyte-secreted hormones, may link obesity with insulin resistance and\/or metabolic and cardiovascular risk factors. We performed a cross-sectional study to investigate the association of adiponectin and resistin with inflammatory markers, hyperlipidemia, and vascular reactivity and an interventional study to investigate whether atorvastatin mediates its beneficial effects by altering adiponectin or resistin levels.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014Associations among vascular reactivity, inflammatory markers, resistin, and adiponectin were assessed cross-sectionally using fasting blood samples obtained from 77 subjects who had diabetes or were at high risk to develop diabetes. The effect of atorvastatin on adiponectin and resistin levels was investigated in a 12-week-long randomized, double-blind, placebo-controlled study.<\/jats:p>\n               <jats:p>RESULTS\u2014In the cross-sectional study, we confirm prior positive correlations of adiponectin with HDL and negative correlations with BMI, triglycerides, C-reactive protein (CRP), and plasma activator inhibitor (PAI)-1 and report a negative correlation with tissue plasminogen activator. The positive association with HDL and the negative association with PAI-1 remained significant after adjusting for sex and BMI. We also confirm prior findings of a negative correlation of resistin with HDL and report for the first time a positive correlation with CRP. All of these associations remained significant after adjusting for sex and BMI. No associations of adiponectin or resistin with any aspects of vascular reactivity were detected. In the interventional study, atorvastatin decreased lipid and CRP levels, but adiponectin and resistin were not specifically altered.<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014We conclude that adiponectin is significantly associated with inflammatory markers, in part, through an underlying association with obesity, whereas resistin\u2019s associations with inflammatory markers appear to be independent of BMI. Lipid profile and inflammatory marker changes produced by atorvastatin cannot be attributed to changes of either adiponectin or resistin.<\/jats:p>","DOI":"10.2337\/diacare.27.10.2450","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:51:27Z","timestamp":1173135087000},"page":"2450-2457","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":314,"title":["Circulating Adiponectin and Resistin Levels in Relation to Metabolic Factors, Inflammatory Markers, and Vascular Reactivity in Diabetic Patients and Subjects at Risk for Diabetes"],"prefix":"10.2337","volume":"27","author":[{"given":"Greeshma K.","family":"Shetty","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis A.","family":"Economides","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Microcirculation Laboratory, Beth Israel Deaconess Medical Center West Campus, Harvard Medical School, Boston, Massachusetts"},{"name":"Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward S.","family":"Horton","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristidis","family":"Veves","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Microcirculation Laboratory, Beth Israel Deaconess Medical Center West Campus, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031216024587900_R1","doi-asserted-by":"crossref","unstructured":"Weyer C, Yudkin JS, Stehouwer CD, Schalkwijk CG, Pratley RE, Tataranni PA: Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis\u2008161: 233\u2013242, 2002","DOI":"10.1016\/S0021-9150(01)00626-8"},{"key":"2022031216024587900_R2","doi-asserted-by":"crossref","unstructured":"Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M: Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo)\u2008120:803\u2013812, 1996","DOI":"10.1093\/oxfordjournals.jbchem.a021483"},{"key":"2022031216024587900_R3","doi-asserted-by":"crossref","unstructured":"Tsao TS, Lodish HF, Fruebis J: ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol\u2008440:213\u2013221, 2002","DOI":"10.1016\/S0014-2999(02)01430-9"},{"key":"2022031216024587900_R4","doi-asserted-by":"crossref","unstructured":"Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun\u2008257:79\u201383, 1999","DOI":"10.1006\/bbrc.1999.0255"},{"key":"2022031216024587900_R5","doi-asserted-by":"crossref","unstructured":"Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, Okazaki Y, Ishii T, Nishikai K, Saruta T: Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond)\u2008103:137\u2013142, 2002","DOI":"10.1042\/cs1030137"},{"key":"2022031216024587900_R6","doi-asserted-by":"crossref","unstructured":"Matsubara M, Maruka S, Katayose S: Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol\u2008147:173\u2013180, 2002","DOI":"10.1530\/eje.0.1470173"},{"key":"2022031216024587900_R7","doi-asserted-by":"crossref","unstructured":"Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature\u2008409:307\u2013312, 2001","DOI":"10.1038\/35053000"},{"key":"2022031216024587900_R8","doi-asserted-by":"crossref","unstructured":"Steppan CM, Lazar MA: Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab\u200813:18\u201323, 2002","DOI":"10.1016\/S1043-2760(01)00522-7"},{"key":"2022031216024587900_R9","doi-asserted-by":"crossref","unstructured":"Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR, Willson TM, Kliewer SA, Hotamisligil GS: Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activator receptor \u03b3-agonists. J Biol Chem\u2008276:25651\u201325653, 2001","DOI":"10.1074\/jbc.C100189200"},{"key":"2022031216024587900_R10","doi-asserted-by":"crossref","unstructured":"Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros C: Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant and diabetic subjects. J Clin Endocrinol Metab\u200888:4848\u20134856, 2003","DOI":"10.1210\/jc.2003-030519"},{"key":"2022031216024587900_R11","doi-asserted-by":"crossref","unstructured":"Silha JV, Krsek M, Hana V, Marek J, Jezkova J, Weiss V, Murphy LJ: Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance. Clin Endocrinol\u200858:736\u2013742, 2003","DOI":"10.1046\/j.1365-2265.2003.01789.x"},{"key":"2022031216024587900_R12","doi-asserted-by":"crossref","unstructured":"Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, Peale FV Jr, Shelton DL, Hebert CC: FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J\u200819:4046\u20134055, 2000","DOI":"10.1093\/emboj\/19.15.4046"},{"key":"2022031216024587900_R13","doi-asserted-by":"crossref","unstructured":"Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation\u2008107:671\u2013674, 2003","DOI":"10.1161\/01.CIR.0000055188.83694.B3"},{"key":"2022031216024587900_R14","doi-asserted-by":"crossref","unstructured":"Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS: Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care\u200826:1745\u20131751, 2003","DOI":"10.2337\/diacare.26.6.1745"},{"key":"2022031216024587900_R15","doi-asserted-by":"crossref","unstructured":"Larsen ML, Illingworth DR: Drug treatment of dyslipoproteinemia. Med Clin North Am\u200878:225\u2013245, 1994","DOI":"10.1016\/S0025-7125(16)30184-5"},{"key":"2022031216024587900_R16","doi-asserted-by":"crossref","unstructured":"Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM: Efficacy and safety of a new HMG CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA\u2008276:128\u2013133, 1996","DOI":"10.1001\/jama.275.2.128"},{"key":"2022031216024587900_R17","doi-asserted-by":"crossref","unstructured":"Kastelein JJ, Isaacsohn JL, Ose L, Hunninghake DB, Frohlich J, Davidson MH, Habib R, Dujovne CA, Crouse JR, Liu M, Melino MR, O\u2019Grady L, Mercuri M, Mitchel YB: Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol\u200886:221\u2013223, 2000","DOI":"10.1016\/S0002-9149(00)00942-5"},{"key":"2022031216024587900_R18","doi-asserted-by":"crossref","unstructured":"Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A: Pravastatin and the development of diabetes mellitus: evidence of a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation\u2008103:357\u2013362, 2001","DOI":"10.1161\/01.CIR.103.3.357"},{"key":"2022031216024587900_R19","doi-asserted-by":"crossref","unstructured":"Economides P, Caselli A, Tiani E, Khaodhiar L, Horton ES, Veves A: The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab\u200889:740\u2013747, 2004","DOI":"10.1210\/jc.2003-031116"},{"key":"2022031216024587900_R20","doi-asserted-by":"crossref","unstructured":"Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med\u2008346:393\u2013403, 2002","DOI":"10.1056\/NEJMoa012512"},{"key":"2022031216024587900_R21","doi-asserted-by":"crossref","unstructured":"Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS: The role of falling leptin in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest\u2008111:1409\u20131421, 2003","DOI":"10.1172\/JCI200317490"},{"key":"2022031216024587900_R22","doi-asserted-by":"crossref","unstructured":"Veves A, Saouaf R, Donaghue V, Mulloly C, Kistler J, Giurini JM, Horton ES, Fielding RA: Aerobic exercise capacity remains normal despite impaired endothelial function in the micro- and macrocirculation of physically active IDDM patients. Diabetes\u200846:1846\u20131852, 1997","DOI":"10.2337\/diabetes.46.11.1846"},{"key":"2022031216024587900_R23","doi-asserted-by":"crossref","unstructured":"Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol\u200839:257\u2013265, 2002","DOI":"10.1016\/S0735-1097(01)01746-6"},{"key":"2022031216024587900_R24","doi-asserted-by":"crossref","unstructured":"Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, Noda T: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem\u2008277:25863\u201325866, 2002","DOI":"10.1074\/jbc.C200251200"},{"key":"2022031216024587900_R25","doi-asserted-by":"crossref","unstructured":"Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med\u20087:941\u2013946, 2001","DOI":"10.1038\/90984"},{"key":"2022031216024587900_R26","doi-asserted-by":"crossref","unstructured":"Bluher M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB, Kahn CR: Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell\u20083:25\u201338, 2002","DOI":"10.1016\/S1534-5807(02)00199-5"},{"key":"2022031216024587900_R27","doi-asserted-by":"crossref","unstructured":"Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes\u200851:1884\u20131888, 2002","DOI":"10.2337\/diabetes.51.6.1884"},{"key":"2022031216024587900_R28","doi-asserted-by":"crossref","unstructured":"Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet\u2008360:57\u201358, 2002","DOI":"10.1016\/S0140-6736(02)09335-2"},{"key":"2022031216024587900_R29","doi-asserted-by":"crossref","unstructured":"Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y: Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood\u200896:1723\u20131732, 2000","DOI":"10.1182\/blood.V96.5.1723.h8001723_1723_1732"},{"key":"2022031216024587900_R30","doi-asserted-by":"crossref","unstructured":"Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation\u2008100:2473\u20132476, 1999","DOI":"10.1161\/01.CIR.100.25.2473"},{"key":"2022031216024587900_R31","doi-asserted-by":"crossref","unstructured":"Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation\u2008103:1057\u20131063, 2001","DOI":"10.1161\/01.CIR.103.8.1057"},{"key":"2022031216024587900_R32","doi-asserted-by":"crossref","unstructured":"Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab\u200886:1930\u20131935, 2001","DOI":"10.1210\/jcem.86.5.7463"},{"key":"2022031216024587900_R33","doi-asserted-by":"crossref","unstructured":"Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes\u200851:2968\u20132974, 2002","DOI":"10.2337\/diabetes.51.10.2968"},{"key":"2022031216024587900_R34","doi-asserted-by":"crossref","unstructured":"Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K: Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care\u200826:2493\u20132499, 2003","DOI":"10.2337\/diacare.26.9.2493"},{"key":"2022031216024587900_R35","doi-asserted-by":"crossref","unstructured":"Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y: Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation\u2008106:2767\u20132770, 2002","DOI":"10.1161\/01.CIR.0000042707.50032.19"},{"key":"2022031216024587900_R36","doi-asserted-by":"crossref","unstructured":"Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J: C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol\u200820:2094\u20132099, 2000","DOI":"10.1161\/01.ATV.20.9.2094"},{"key":"2022031216024587900_R37","unstructured":"Vaughan DE: PAI-1 and vascular disease in diabetes mellitus. In Diabetes and Cardiovascular Disease. Johnston MT, Veves A, Eds. Totowa, NJ, Humana Press, 2000, p. 237\u2013247"},{"key":"2022031216024587900_R38","doi-asserted-by":"crossref","unstructured":"Devaraj S, Chan AV, Jialal I: \u03b1-Tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients. Diabetes Care\u200825:525\u2013529, 2002","DOI":"10.2337\/diacare.25.3.524"},{"key":"2022031216024587900_R39","doi-asserted-by":"crossref","unstructured":"Juhan VI, Alessi MC, Nalbonne G: Fibrinolysis and athero-thrombosis. Curr Opin Lipidol\u20084:477\u2013483, 1993","DOI":"10.1097\/00041433-199312000-00009"},{"key":"2022031216024587900_R40","unstructured":"Vgontzas AN, Bixler EO, Papanicolaou DA, Chrousos GP: Chronic systemic inflammation in overweight and obese adults. JAMA\u2008283:2235, 2000"},{"key":"2022031216024587900_R41","doi-asserted-by":"crossref","unstructured":"Go\u0301mez-Ambrosi J, Fru\u0308hbeck G: Do resistin and resistin-like molecules also link obesity to inflammatory diseases? Ann Intern Med\u2008135:306\u2013307, 2001","DOI":"10.7326\/0003-4819-135-4-200108210-00030"},{"key":"2022031216024587900_R42","doi-asserted-by":"crossref","unstructured":"Tan KCB, Xu A, Chow WS, Lam MCW, Ai VHG, Tam SCF, Lam KSL: Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab\u200889:765\u2013769, 2004","DOI":"10.1210\/jc.2003-031012"},{"key":"2022031216024587900_R43","doi-asserted-by":"crossref","unstructured":"Fernandez-Real JM, Castro A, Vazquez G, Casamitjana R, Lopez-Bermejo A, Penarroja G, Ricart W: Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care\u200827:739\u2013745, 2004","DOI":"10.2337\/diacare.27.3.739"},{"key":"2022031216024587900_R44","doi-asserted-by":"crossref","unstructured":"Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation\u2008101:207\u2013213, 2000","DOI":"10.1161\/01.CIR.101.2.207"},{"key":"2022031216024587900_R45","doi-asserted-by":"crossref","unstructured":"Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A\u200895:8880\u20138885, 1998","DOI":"10.1073\/pnas.95.15.8880"},{"key":"2022031216024587900_R46","doi-asserted-by":"crossref","unstructured":"Sakai M, Kobori S, Matsumura T, Biwa T, Sato Y, Takemura T, Hakamata H, Horiuchi S, Shichiri M: HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis\u2008133:51\u201359, 1997","DOI":"10.1016\/S0021-9150(97)00118-4"},{"key":"2022031216024587900_R47","doi-asserted-by":"crossref","unstructured":"Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) investigators. Circulation\u2008100:230\u2013235, 1999","DOI":"10.1161\/01.CIR.100.3.230"},{"key":"2022031216024587900_R48","doi-asserted-by":"crossref","unstructured":"Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest\u2008101:2711\u20132719, 1998","DOI":"10.1172\/JCI1500"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/27\/10\/2450\/561706\/zdc01004002450.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/27\/10\/2450\/561706\/zdc01004002450.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T16:19:46Z","timestamp":1647101986000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/27\/10\/2450\/23246\/Circulating-Adiponectin-and-Resistin-Levels-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,1]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.27.10.2450","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,1]]}}}